• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

β-内酰胺类和大环内酯类抗生素对幽门螺杆菌的活性。

Activities of beta-lactams and macrolides against Helicobacter pylori.

作者信息

Hassan I J, Stark R M, Greenman J, Millar M R

机构信息

Pathology and Microbiology Department, University of Bristol, Bristol BS2 8HW, United Kingdom.

出版信息

Antimicrob Agents Chemother. 1999 Jun;43(6):1387-92. doi: 10.1128/AAC.43.6.1387.

DOI:10.1128/AAC.43.6.1387
PMID:10348758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC89284/
Abstract

A continuous-culture system (chemostat) was used to study the activities of beta-lactam antimicrobial agents, clarithromycin, and 14-OH-clarithromycin against slowly growing Helicobacter pylori NCTC 11637. H. pylori was grown to steady state before exposure to these antimicrobial agents at x8 the MIC. The bactericidal actions of combinations of amoxicillin and clarithromycin were also studied. Viable counts (numbers of CFU per milliliter) were determined at 2-h intervals for 12 h and at 20 h after the addition of antibiotics. The effects of pH changes (6.5 to 7.4) on the activities of amoxicillin, clarithromycin, and the combination of these against H. pylori NCTC 11637 were also studied. Viable counts following exposure to ampicillin, cefixime, ceftazidime, cefuroxime, cefotaxime, azlocillin, and piperacillin at 20 h showed bacteriostatic activity. Imipenem, meropenem, amoxicillin, clarithromycin, and 14-OH-clarithromycin reduced the viable counts by 3 log10 CFU/ml (>/=99.9% killing). Imipenem was the most rapidly bactericidal against H. pylori NCTC 11637. Results of the pH experiments showed that amoxicillin was bactericidal at pHs 6.5 to 7. 4. Clarithromycin was bactericidal at pH 7.0 to 7.4 but was bacteriostatic at pH 6.5. The combination of amoxicillin and clarithromycin was bactericidal at pHs 6.5 and 7.0. A batch culture (flask system) was also used to investigate 12 strains of H. pylori for their susceptibilities to beta-lactams, clarithromycin, and/or 14-OH-clarithromycin in order to determine whether results from the chemostat model can be reproduced with batch cultures. Results of the chemostat time-kill kinetic study were reproducible in our batch culture flask system. The role of carbapenems in the eradication of H. pylori should be investigated.

摘要

采用连续培养系统(恒化器)研究β-内酰胺类抗菌药物、克拉霉素和14-羟基克拉霉素对缓慢生长的幽门螺杆菌NCTC 11637的活性。幽门螺杆菌在以8倍最低抑菌浓度(MIC)暴露于这些抗菌药物之前先培养至稳定状态。还研究了阿莫西林和克拉霉素联合用药的杀菌作用。在添加抗生素后,每隔2小时测定12小时内以及20小时时的活菌计数(每毫升菌落形成单位数)。还研究了pH变化(6.5至7.4)对阿莫西林、克拉霉素及其联合用药针对幽门螺杆菌NCTC 11637活性的影响。在20小时时,暴露于氨苄西林、头孢克肟、头孢他啶、头孢呋辛、头孢噻肟、阿洛西林和哌拉西林后的活菌计数显示出抑菌活性。亚胺培南、美罗培南、阿莫西林、克拉霉素和14-羟基克拉霉素使活菌计数降低3 log10 CFU/ml(杀菌率≥99.9%)。亚胺培南对幽门螺杆菌NCTC 11637的杀菌速度最快。pH实验结果表明,阿莫西林在pH 6.5至7.4时具有杀菌作用。克拉霉素在pH 7.0至7.4时具有杀菌作用,但在pH 6.5时具有抑菌作用。阿莫西林和克拉霉素联合用药在pH 6.5和7.0时具有杀菌作用。还采用分批培养(烧瓶系统)研究了12株幽门螺杆菌对β-内酰胺类药物、克拉霉素和/或14-羟基克拉霉素的敏感性,以确定恒化器模型的结果能否在分批培养中重现。恒化器时间-杀菌动力学研究的结果在我们的分批培养烧瓶系统中具有可重复性。应研究碳青霉烯类药物在根除幽门螺杆菌中的作用。

相似文献

1
Activities of beta-lactams and macrolides against Helicobacter pylori.β-内酰胺类和大环内酯类抗生素对幽门螺杆菌的活性。
Antimicrob Agents Chemother. 1999 Jun;43(6):1387-92. doi: 10.1128/AAC.43.6.1387.
2
Absence of a post-antibiotic effect (PAE) of beta-lactams against Helicobacter pylori NCTC 11637.
J Antimicrob Chemother. 1998 Nov;42(5):661-3. doi: 10.1093/jac/42.5.661.
3
Bactericidal activity of antimicrobial agents against slowly growing Helicobacter pylori.抗菌剂对生长缓慢的幽门螺杆菌的杀菌活性。
Antimicrob Agents Chemother. 1992 Jan;36(1):185-7. doi: 10.1128/AAC.36.1.185.
4
Comparative in vitro antimicrobial susceptibility and synergistic activity of antimicrobial combinations against Helicobacter pylori isolates in Taiwan.台湾幽门螺杆菌分离株的体外比较抗菌药敏试验和抗菌联合用药的协同活性。
J Microbiol Immunol Infect. 2015 Feb;48(1):72-9. doi: 10.1016/j.jmii.2012.08.021. Epub 2012 Oct 1.
5
Kill kinetics of antimicrobial agents against Helicobacter pylori.抗菌剂对幽门螺杆菌的杀灭动力学
J Antimicrob Chemother. 1996 Oct;38(4):719-25. doi: 10.1093/jac/38.4.719.
6
In vitro activity of clarithromycin against intracellular Helicobacter pylori.克拉霉素对细胞内幽门螺杆菌的体外活性。
Antimicrob Agents Chemother. 2001 May;45(5):1568-71. doi: 10.1128/AAC.45.5.1568-1571.2001.
7
[In vitro activities of faropenem against clarithromycin resistance Helicobacter pylori isolates].
Kansenshogaku Zasshi. 1998 Mar;72(3):207-10. doi: 10.11150/kansenshogakuzasshi1970.72.207.
8
Inhibitory and bactericidal activity of rokitamycin against Helicobacter pylori and morphological alterations.罗他霉素对幽门螺杆菌的抑制和杀菌活性及形态学改变
J Chemother. 1996 Dec;8(6):425-31. doi: 10.1179/joc.1996.8.6.425.
9
Effect of plaunotol in combination with clarithromycin or amoxicillin on Helicobacter pylori in vitro and in vivo.普伐他汀与克拉霉素或阿莫西林联合使用对幽门螺杆菌的体内外作用
J Antimicrob Chemother. 2002 Jul;50(1):133-6. doi: 10.1093/jac/dkf094.
10
In vitro activity of fosfomycin alone and in combination with amoxicillin, clarithromycin and metronidazole against Helicobacter pylori compared with combined clarithromycin and metronidazole.单独使用磷霉素以及磷霉素与阿莫西林、克拉霉素和甲硝唑联合使用对幽门螺杆菌的体外活性与克拉霉素和甲硝唑联合使用的比较。
Eur J Clin Microbiol Infect Dis. 2005 Apr;24(4):276-9. doi: 10.1007/s10096-005-1307-9.

引用本文的文献

1
Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: a single-center, open-label, non-inferiority, randomized controlled trial.海南地区 vonoprazan 双重疗法、四联疗法与标准四联疗法治疗幽门螺杆菌感染的比较:一项单中心、开放标签、非劣效、随机对照试验。
BMC Gastroenterol. 2024 Apr 12;24(1):131. doi: 10.1186/s12876-024-03225-8.
2
Factors Affecting the Intraluminal Therapy for Infection.影响腔内感染治疗的因素。
Microorganisms. 2022 Feb 11;10(2):415. doi: 10.3390/microorganisms10020415.
3
Efficacy of dexlansoprazole-based triple therapy for infections.基于右兰索拉唑的三联疗法治疗感染的疗效。
Therap Adv Gastroenterol. 2019 Sep 5;12:1756284819870960. doi: 10.1177/1756284819870960. eCollection 2019.
4
Vonoprazan-based therapy for eradication: experience and clinical evidence.基于沃克帕唑的根除治疗:经验与临床证据。
Therap Adv Gastroenterol. 2016 Nov;9(6):845-852. doi: 10.1177/1756283X16668093. Epub 2016 Sep 22.
5
A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection.一项基于右兰索拉唑缓释片的三联疗法治疗幽门螺杆菌感染的随机对照试验性研究
Medicine (Baltimore). 2016 Mar;95(11):e2698. doi: 10.1097/MD.0000000000002698.
6
Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy.吡啶二氮杂卓胺类化合物是通过抑制谷氨酸消旋酶来抑制幽门螺杆菌生长的选择性治疗药物,但预计需要血浆中持续保持较高水平才能达到临床疗效。
Antimicrob Agents Chemother. 2015 Apr;59(4):2337-42. doi: 10.1128/AAC.04410-14. Epub 2015 Feb 2.
7
In vitro antibacterial and morphological effects of the urushiol component of the sap of the Korean lacquer tree (Rhus vernicifera Stokes) on Helicobacter pylori.漆树汁漆酚成分对幽门螺杆菌的体外抗菌和形态学效应。
J Korean Med Sci. 2010 Mar;25(3):399-404. doi: 10.3346/jkms.2010.25.3.399. Epub 2010 Feb 17.

本文引用的文献

1
The estimation of the bactericidal power of the blood.血液杀菌能力的评估。
J Hyg (Lond). 1938 Nov;38(6):732-49. doi: 10.1017/s002217240001158x.
2
Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.欧洲幽门螺杆菌感染管理的当前概念。马斯特里赫特共识报告。欧洲幽门螺杆菌研究小组。
Gut. 1997 Jul;41(1):8-13. doi: 10.1136/gut.41.1.8.
3
In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori.克拉霉素和14-羟基克拉霉素与阿莫西林或次水杨酸铋对幽门螺杆菌的体外协同试验。
Antimicrob Agents Chemother. 1997 Jul;41(7):1607-8. doi: 10.1128/AAC.41.7.1607.
4
Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640.新型口服碳青霉烯类药物DZ-2640的母体化合物DU-6681a的抗菌活性
Antimicrob Agents Chemother. 1997 Jun;41(6):1260-8. doi: 10.1128/AAC.41.6.1260.
5
Kill kinetics of antimicrobial agents against Helicobacter pylori.抗菌剂对幽门螺杆菌的杀灭动力学
J Antimicrob Chemother. 1996 Oct;38(4):719-25. doi: 10.1093/jac/38.4.719.
6
Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant.影响幽门螺杆菌生长及抗生素敏感性的因素:pH值和尿素对野生型菌株及脲酶缺陷型突变体存活的影响
J Med Microbiol. 1996 Jun;44(6):425-33. doi: 10.1099/00222615-44-6-425.
7
Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state.奥美拉唑对稳态下血浆及胃组织中克拉霉素浓度的影响。
Antimicrob Agents Chemother. 1995 Sep;39(9):2078-83. doi: 10.1128/AAC.39.9.2078.
8
Background and historical considerations of Helicobacter pylori.
Gastroenterol Clin North Am. 1993 Mar;22(1):1-4.
9
Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease.幽门螺杆菌的治疗可降低消化性溃疡疾病的再出血率。
Scand J Gastroenterol. 1993 Nov;28(11):939-42. doi: 10.3109/00365529309098288.
10
In vitro susceptibility testing of Helicobacter pylori to antimicrobial agents: basis for treatment or microbiologists' obsession?幽门螺杆菌对抗菌药物的体外药敏试验:治疗依据还是微生物学家的执念?
Zentralbl Bakteriol. 1993 Sep;280(1-2):227-38. doi: 10.1016/s0934-8840(11)80960-6.